A Phase 2 interventional study of Abiraterone and Leuprolide in Prostate Cancer, sponsored by Janssen Research & Development, LLC. Completed at 4 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-17.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing abiraterone in Prostatic Neoplasms — 17 open to participants now, 37 under way, 5 of them phase 3. abiraterone · Prostatic Neoplasms.
Among the 126 studies testing abiraterone in Prostatic Neoplasms, this one is the 55th largest by enrollment, is one of 4 that started in 2009, is one of 79 in phase 2, and was the 11th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 126 studies testing abiraterone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 30+ · Men only
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
SMED Clinical Research · Sites in Argentina, Spain
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
abiraterone: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 90 · Phase 3 12 · Phase 4 4
First in 2005; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is close to the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 51 across the 126 interventional studies. Of the 75 that completed or were terminated, 47 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 40th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2009, is one of 20 in phase 2, and was the 15th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
10 of the studies testing abiraterone in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT07299292SMED Clinical ResearchCastration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 126 studies testing abiraterone in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors) who are suitable candidates for prostatectomy (surgery to remove all or part of the prostate gland).
This is an open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), and multi-center (conducted in more than one center) study of abiraterone in male participants with prostate cancer. The duration of study will be approximately 24-32 weeks per participant. The study consists of 4 parts: Screening (that is, 30 days before study commences on Day 1); Treatment (abiraterone acetate 1000 milligram per day or leuprolide acetate as 22.5 milligram intramuscular injection [injection of a substance into a muscle] or prednisone 5 mg once daily); Prostatectomy (Week 24); and Follow-up ( 4-8 weeks after prostatectomy). Participants will receive either abiraterone, leuprolide and prednisone for 24 weeks (that is, Group 1) or leuprolide once every 12 weeks up to Week 24 then abiraterone and prednisone from Week 13 to 24 (that is, Group 2). All the eligible participants will be randomly assigned to 1 of the 2 treatment groups. Efficacy will be evaluated primarily through the concentrations of testosterone and dihydrotestosterone from prostate tissues at Week 12. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
Drug: Abiraterone · Drug: Leuprolide · Drug: Prednisone
Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.
Drug: Abiraterone · Drug: Leuprolide · Drug: Prednisone
Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
Also known as: CB7630
Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
Testosterone Concentration in Prostate Tissue
Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Abiraterone acetate affects sources of testosterone in the body (ie, adrendal gland and prostate tumor). Testosterone concentration was measured in prostate tissues after exposure to study treatments at Week 12.
Time frame: Week 12
Dihydrotestosterone (DHT) Concentration in Prostate Tissue
The DHT is a potent androgenic metabolite of testosterone and the concentration of DHT was measured in prostate tissues after exposure to study treatments at Week 12.
Time frame: Week 12
Testosterone and Dihydrotestosterone (DHT) Concentration in Prostate Tissue
Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Dihydrotestosterone (DHT) is a potent androgenic metabolite of testosterone. Testosterone and DHT concentration was measured in prostate tissues after exposure to study treatments at Week 24.
Time frame: Week 24
Androstenedione and Dehydroepiandrosterone (DHEA) Concentrations in Prostate Tissue
Androstenedione is a steroid (a group of polycyclic compounds closely related biochemically to terpenes, for example, cholesterol, numerous hormones), that is produced in the testis, ovary and the adrenal cortex, and depending on the tissue type, androstenedione can serve as a precursor to testosterone, estrone and estradiol. The DHEA is a major steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Androstenedione and DHEA concentration was measured in prostate tissues at Week 12 and 24.
Time frame: Week 12 and 24
Serum Levels of Androgens
Serum concentrations of testosterone, DHT, androsterone, DHEA, DHEA-Sulfate, DHEA-Glucuronide and delta-4-androstenedione were measured at Weeks 12 and 24.
Time frame: Week 12 and 24
Percentage of Participants With Prostate-specific Antigen (PSA) Response
The PSA response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criterion which is, percentage of participants with PSA less than or equal to 0.2 nanogram/milliliter at Weeks 12 and 24 after androgen deprivation.
Time frame: Weeks 12 and 24
Percentage of Participants With Pathologic Complete Response (CR)
Complete response is defined as a disappearance of all target lesions and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criterion.
Time frame: Week 24
Number of Participants With Tumor Expression of Androgen Receptor (AR) Regulated Genes at Week 24
Tumor expression of AR regulated genes determined by real-time polymerase chain reaction (RT PCR). PCR is an in vitro method for producing large amounts of specific deoxyribonucleic acid (DNA) or ribonucleic acid fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). RT PCR is a method used for detecting the amplified DNA products from the PCR as they accumulate instead of at the end of the reaction.
Time frame: Week 24
Correlation Between Molecular and Protein Expression With Intracellular Androgen Levels and Pathologic Response to Study Treatment
Molecular and protein expression was correlated with intracellular androgen levels and pathologic response to study treatment.
Time frame: Week 24
| Milestone | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Started | 30 | 28 |
| Completed | 28 | 26 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Abiraterone acetate affects sources of testosterone in the body (ie, adrendal gland and prostate tumor). Testosterone concentration was measured in prostate tissues after exposure to study treatments at Week 12.
| Picogram per milligram (pg/mg) | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Testosterone Concentration in Prostate Tissue | 0.089 ± 0.0637 | 0.228 ± 0.3788 |
Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Dihydrotestosterone (DHT) is a potent androgenic metabolite of testosterone. Testosterone and DHT concentration was measured in prostate tissues after exposure to study treatments at Week 24.
| Picogram per milligram (pg/mg) | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Testosterone | 0.216 ± 0.6707 | 0.062 ± 0.0340 |
| DHT | 1.340 ± 3.5099 | 2.456 ± 6.3901 |
Androstenedione is a steroid (a group of polycyclic compounds closely related biochemically to terpenes, for example, cholesterol, numerous hormones), that is produced in the testis, ovary and the adrenal cortex, and depending on the tissue type, androstenedione can serve as a precursor to testosterone, estrone and estradiol. The DHEA is a major steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Androstenedione and DHEA concentration was measured in prostate tissues at Week 12 and 24.
| Picogram per milligram (pg/mg) | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Androstenedione: Week 12 (n=28,27) | 0.082 ± 0.0525 | 0.277 ± 0.1729 |
| Androstenedione: Week 24 (n=28,26) | 0.090 ± 0.0879 | 0.070 ± 0.0403 |
| DHEA: Week 12 (n=28,27) | 1.994 ± 5.0266 | 29.241 ± 26.9800 |
| DHEA: Week 24 (n=28,26) | 3.138 ± 8.6692 | 2.170 ± 3.7095 |
Serum concentrations of testosterone, DHT, androsterone, DHEA, DHEA-Sulfate, DHEA-Glucuronide and delta-4-androstenedione were measured at Weeks 12 and 24.
| Nanogram per deciliter (ng/dL) | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Testosterone: Week 12 (n=28,28) | 1.049 ± 1.0374 | 10.014 ± 12.5981 |
| Testosterone: Week 24 (n=25,25) | 0.648 ± 0.4975 | 3.122 ± 12.6460 |
| DHT: Week 12 (n=28,28) | 6.143 ± 8.9868 | 5.797 ± 5.9816 |
| DHT: Week 24 (n=26,26) | 5.932 ± 9.1599 | 6.730 ± 15.7929 |
| Androsterone: Week 12 (n=28,28) | 0.619 ± 0.4473 | 3.100 ± 5.8891 |
| Androsterone: Week 24 (26,26) | 1.752 ± 6.3226 | 0.500 ± 0.0000 |
| DHEA: Week 12 (n=28,28) | 10.684 ± 27.2814 | 180.307 ± 133.6277 |
| DHEA: Week 24 (n=26,26) | 20.922 ± 64.2594 | 7.617 ± 14.5386 |
| DHEA-Glucuronide: Week 12 (n=29,28) | 69.724 ± 184.2399 | 583.036 ± 879.7514 |
| DHEA-Glucuronide: Week 24 (n=27,27) | 51.675 ± 148.9412 | 51.759 ± 95.0666 |
| DHEA-Sulfate: Week 12 (n=28,28) | 7156.270 ± 22406.7048 | 133338.875 ± 108819.6403 |
| DHEA-Sulfate: Week 24 (n=26,26) | 9047.406 ± 27844.7883 | 9207.345 ± 30897.5488 |
| Delta-4-Androstenedione:Week 12(n=28,28) | 3.315 ± 3.3858 | 33.330 ± 26.8110 |
| Delta-4-Androstenedione:Week 24(n=26,26) | 5.192 ± 10.8654 | 2.831 ± 1.1596 |
The PSA response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criterion which is, percentage of participants with PSA less than or equal to 0.2 nanogram/milliliter at Weeks 12 and 24 after androgen deprivation.
| Percentage of participants | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Week 12 | 86.7 ± 0.0637 | 3.6 ± 0.3788 |
| Week 24 | 86.7 | 82.1 |
Complete response is defined as a disappearance of all target lesions and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criterion.
| Percentage of participants | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Percentage of Participants With Pathologic Complete Response (CR) | 10.3 ± 0.0637 | 3.7 ± 0.3788 |
Tumor expression of AR regulated genes determined by real-time polymerase chain reaction (RT PCR). PCR is an in vitro method for producing large amounts of specific deoxyribonucleic acid (DNA) or ribonucleic acid fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). RT PCR is a method used for detecting the amplified DNA products from the PCR as they accumulate instead of at the end of the reaction.
No measurements were reported for this outcome.
Molecular and protein expression was correlated with intracellular androgen levels and pathologic response to study treatment.
No measurements were reported for this outcome.
The DHT is a potent androgenic metabolite of testosterone and the concentration of DHT was measured in prostate tissues after exposure to study treatments at Week 12.
| Picogram per milligram (pg/mg) | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Dihydrotestosterone (DHT) Concentration in Prostate Tissue | 4.311 ± 21.6213 | 2.170 ± 3.4589 |
Collected over Baseline up to Week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abiraterone Plus Leuprolide Plus Prednisone | — | 6/30 (20%) | 30/30 (100%) |
| Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone | — | 7/28 (25%) | 28/28 (100%) |
| Event | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 2/30 | 1/28 |
| Pituitary infarctionEndocrine disorders | 0/30 | 1/28 |
| Gastrointestinal perforationGastrointestinal disorders | 0/30 | 1/28 |
| IleusGastrointestinal disorders | 0/30 | 1/28 |
| VomitingGastrointestinal disorders | 0/30 | 1/28 |
| Hernia obstructiveGeneral disorders | 0/30 | 1/28 |
| PyrexiaGeneral disorders | 0/30 | 1/28 |
| Infected lymphoceleInfections and infestations | 1/30 | 1/28 |
| InfectionInfections and infestations | 0/30 | 1/28 |
| Staphylococcal infectionInfections and infestations | 0/30 | 1/28 |
| Event | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone |
|---|---|---|
| Hot flushVascular disorders | 24/30 | 27/28 |
| FatigueGeneral disorders | 13/30 | 16/28 |
| Alanine aminotransferase increasedInvestigations | 12/30 | 16/28 |
| Aspartate aminotransferase increasedInvestigations | 14/30 | 15/28 |
| HypokalaemiaMetabolism and nutrition disorders | 6/30 | 6/28 |
| Libido decreasedPsychiatric disorders | 6/30 | 5/28 |
| AnaemiaBlood and lymphatic system disorders | 4/30 | 5/28 |
| HyperglycaemiaMetabolism and nutrition disorders | 4/30 | 5/28 |
| HeadacheNervous system disorders | 5/30 | 5/28 |
| InsomniaPsychiatric disorders | 3/30 | 5/28 |
| Age Continuous(years) | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone | Total |
|---|---|---|---|
| Mean | 61.0 ± 6.67 | 56.9 ± 5.30 | 59.0 ± 6.35 |
| Sex: Female, Male(Participants) | Abiraterone Plus Leuprolide Plus Prednisone | Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 30 | 28 | 58 |
The record gives a start of Nov 2009, a primary completion of Feb 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abiraterone · Leuprolide · Prednisone
Janssen Research & Development, LLC →